nup189 Antibody

What is NUP188 and what role does it play in cellular function?

NUP188 is a component of the nuclear pore complex (NPC), which is essential for trafficking across the nuclear envelope. Research indicates that NUP188 is specifically required for proper protein transport into the nucleus, making it a critical factor in nucleocytoplasmic transport mechanisms . The protein has a molecular weight of approximately 196 kDa and functions as part of the structural scaffold of the nuclear pore complex. Understanding its role is crucial for investigations into nuclear transport dysfunctions in various cellular processes and disease states .

What types of NUP188 antibodies are available for research applications?

The primary types available are rabbit polyclonal antibodies, which have been developed against specific peptide regions of human NUP188. These antibodies vary in their immunogen characteristics, with some targeting recombinant fragments within the amino acid region 250-400 of human NUP188 , while others are developed against synthesized peptides derived from human NUP188 . The antibodies are typically available in unconjugated form and are offered at various concentrations, commonly around 0.05 mg/ml for research applications .

What are the standard applications for NUP188 antibodies?

NUP188 antibodies have been validated for several standard research applications, including:

The optimal dilutions should be determined experimentally depending on the specific research conditions and sample types .

How should researchers optimize NUP188 antibody dilution for specific applications?

For optimal antibody dilution determination, researchers should employ a systematic titration approach. Begin with the manufacturer's recommended range (e.g., 1:50-1:200 for IHC as suggested in the literature) and prepare a dilution series. Test these dilutions on positive control samples known to express NUP188, alongside negative controls. Evaluate signal-to-noise ratio, specificity, and background staining intensity at each dilution. For Western blotting, perform a similar titration series, starting with approximately 1:1000 dilution and adjusting based on band intensity and background. Document the optimization process systematically for protocol reproducibility. Note that optimal dilutions may need further adjustment based on sample preparation methods, fixation procedures, and detection systems used in your specific experimental setup.

What are the recommended sample preparation protocols for NUP188 detection by immunofluorescence?

For optimal immunofluorescence detection of NUP188, paraformaldehyde fixation has shown effective results as demonstrated in published protocols using SiHa cells . The recommended procedure includes:

• Grow cells on coverslips to 70-80% confluency

• Fix with 4% paraformaldehyde in PBS for 15 minutes at room temperature

• Permeabilize cells with 0.2% Triton X-100 for 10 minutes

• Block with 3% BSA in PBS for 1 hour

• Incubate with primary NUP188 antibody at approximately 4 μg/ml overnight at 4°C

• Wash 3x with PBS

• Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

• Counterstain nuclei with DAPI and mount

This protocol helps preserve the nuclear envelope structure where NUP188 is localized, which is critical for accurate assessment of its distribution pattern .

How can researchers address non-specific binding when using NUP188 antibodies?

Non-specific binding when using NUP188 antibodies can significantly impact experimental interpretation. To address this issue, implement the following methodological approaches:

• Increase blocking stringency: Extend blocking time to 2 hours using 5% BSA or 5% normal serum from the species in which the secondary antibody was raised.

• Optimize antibody concentration: Test multiple dilutions beyond manufacturer recommendations, as NUP188 antibodies may require significant optimization (as seen with the 1:20 dilution required for some IHC applications) .

• Include specific competitors: For peptide-derived antibodies, pre-incubate with excess immunizing peptide as a specificity control.

• Modify washing protocol: Implement additional washing steps with higher salt concentration buffers (up to 500 mM NaCl) to disrupt low-affinity non-specific interactions.

• Validate with multiple antibodies: Compare staining patterns using antibodies raised against different epitopes of NUP188 to confirm specificity.

• Include proper controls: Always include samples known to be negative for NUP188 and antibody-omission controls in experimental design.

These approaches have proven effective in optimizing signal-to-noise ratio for nuclear pore complex proteins in various experimental contexts .

What are the most common false-positive patterns observed with NUP188 antibodies and how can they be distinguished from true signals?

When working with NUP188 antibodies, researchers should be aware of several distinctive false-positive patterns and implement verification strategies:

• Diffuse nuclear staining vs. nuclear rim pattern: Authentic NUP188 staining should produce a punctate nuclear rim pattern reflecting its localization at nuclear pore complexes . Diffuse nuclear staining likely represents non-specific binding.

• Cytoplasmic granular staining: While some nucleoporins shuttle between nucleus and cytoplasm, extensive cytoplasmic granular staining with NUP188 antibodies often indicates cross-reactivity with other proteins.

• Verification approaches:

  • Perform peptide competition assays to confirm antibody specificity

  • Compare staining pattern with established nuclear envelope markers

  • Corroborate results using orthogonal detection methods (e.g., fluorescent protein tagging)

  • Validate with siRNA knockdown experiments to confirm signal reduction

• Controls to implement:

  • Tissue-specific positive controls with known NUP188 expression

  • Technical negative controls (secondary antibody only)

  • Biological negative controls (NUP188-deficient cells if available)

These verification strategies are critical for ensuring experimental rigor when investigating nuclear pore proteins, which can exhibit complex localization patterns .

How can NUP188 antibodies be effectively utilized in studying nuclear transport defects in disease models?

For investigating nuclear transport defects in disease models using NUP188 antibodies, researchers should implement the following methodological approach:

• Comparative quantitative analysis: Develop a standardized quantification method for NUP188 immunostaining intensity at the nuclear envelope. Use high-resolution confocal microscopy with standardized acquisition parameters for accurate quantification across healthy and diseased samples.

• Co-localization studies: Perform dual immunostaining with NUP188 antibody and other NPC components or transport factors to assess relative distribution changes in disease states. Calculate Pearson's correlation coefficients to quantify changes in co-localization patterns.

• Live-cell imaging compatibility: While antibodies themselves aren't suitable for live-cell studies, correlative approaches can be developed where live imaging of nuclear transport is followed by fixed-cell immunostaining with NUP188 antibodies.

• Proximity ligation assays (PLA): Combine NUP188 antibodies with antibodies against transport substrates in PLA assays to visualize and quantify altered interactions in disease models with single-molecule sensitivity.

• Super-resolution microscopy applications: Employ STORM or PALM microscopy with NUP188 antibodies to detect nanoscale changes in NPC organization that may not be visible with conventional microscopy.

This multifaceted approach allows for comprehensive characterization of nuclear transport defects in various disease contexts, including cancer and neurodegenerative disorders where nuclear transport disruption is increasingly recognized as a pathogenic mechanism .

What are the considerations for using NUP188 antibodies in multiplexed immunofluorescence experiments?

When designing multiplexed immunofluorescence experiments incorporating NUP188 antibodies, several critical factors must be addressed:

• Antibody compatibility assessment:

  • Verify that all primary antibodies originate from different host species to prevent cross-reactivity

  • If using multiple rabbit-derived antibodies (common for NUP188), implement sequential staining with complete stripping between rounds, or use directly conjugated primary antibodies

• Spectral separation strategy:

  • Design fluorophore combinations with minimal spectral overlap

  • Perform single-color controls to establish bleed-through correction parameters

  • Consider using spectral unmixing algorithms for closely overlapping fluorophores

• Signal amplification considerations:

  • For weak NUP188 signals, implement tyramide signal amplification (TSA) with careful titration

  • When using amplification systems, increase washing stringency to minimize background

• Protocol optimization:

  • Test antibody combinations on control samples before experimental samples

  • Determine optimal order of antibody application (typically start with lowest concentration antibody)

  • Adjust individual antibody concentrations within the multiplex compared to single-staining protocols

• Validation approaches:

  • Compare multiplex results with single-antibody staining patterns

  • Include appropriate blocking steps between antibody incubations

  • Validate staining pattern with orthogonal methods

This systematic approach ensures reliable data generation when incorporating NUP188 detection into complex multiplexing experiments, enabling comprehensive analysis of nuclear transport components in their cellular context .

How should researchers quantify NUP188 expression levels from immunoblotting experiments?

For accurate quantification of NUP188 expression levels from immunoblotting experiments, researchers should implement the following methodological guidelines:

• Standardized loading controls:

  • Use structural nuclear envelope proteins (e.g., Lamin B) rather than general housekeeping proteins when normalizing NUP188 levels

  • Validate that loading control expression remains stable under your experimental conditions

• Quantification procedure:

  • Employ densitometry software (ImageJ, Image Studio, etc.) with consistent analysis parameters

  • Define signal measurement areas of identical size across all samples

  • Subtract local background for each lane individually

  • Calculate NUP188 signal relative to loading control

• Statistical considerations:

  • Perform at least three biological replicates for statistical validity

  • Apply appropriate statistical tests based on data distribution

  • Report both normalized values and statistical significance

• Technical validation:

  • Confirm antibody linearity by analyzing a dilution series of lysate

  • Establish detection limits for your specific experimental system

  • Verify that measurements fall within the linear range of detection

• Reporting standards:

  • Present both representative blot images and quantification graphs

  • Include molecular weight markers to confirm target specificity (196 kDa for NUP188)

  • Clearly indicate antibody dilution and exposure parameters

This comprehensive approach ensures reproducible and reliable quantification of NUP188 protein levels across experimental conditions, enabling meaningful comparison between control and experimental groups .

What criteria should be used to evaluate NUP188 antibody specificity in immunohistochemistry applications?

When evaluating NUP188 antibody specificity in immunohistochemistry applications, researchers should employ a systematic multi-parameter assessment framework:

• Expected localization pattern:

  • Authentic NUP188 staining should show distinct nuclear rim localization

  • The pattern should be punctate rather than continuous, reflecting NPC distribution

  • Assess concordance with known subcellular distribution of NUP188 at the nuclear envelope

• Tissue expression profile validation:

  • Compare staining intensity across multiple tissue types with known differential NUP188 expression

  • Verify correlation between protein and mRNA expression data from public databases

  • Expect higher expression in metabolically active tissues with significant nuclear transport demands

• Controls for specificity confirmation:

  • Peptide competition assays using the immunizing peptide

  • Comparison of staining patterns between multiple NUP188 antibodies targeting different epitopes

  • Inclusion of tissues known to be negative or positive for NUP188 expression

• Technical validation parameters:

  • Antibody titration series to determine optimal concentration (noted to be as dilute as 1:20 for some applications)

  • Assessment of different antigen retrieval methods on staining pattern

  • Evaluation of fixation effects on epitope accessibility

• Correlation with orthogonal methods:

  • Confirmation with RNA in situ hybridization where applicable

  • Validation with genetic models (knockdown/knockout) where available

  • Correlation with Western blot results from the same tissues

This comprehensive evaluation framework ensures that the observed IHC staining authentically represents NUP188 distribution, minimizing misinterpretation due to antibody cross-reactivity or technical artifacts .

How can NUP188 antibodies be utilized in studying the relationship between nuclear pore complex dysfunction and disease pathogenesis?

NUP188 antibodies offer powerful tools for investigating the emerging connections between nuclear pore complex (NPC) dysfunction and disease pathogenesis through the following methodological approaches:

• Differential expression analysis in disease tissues:

  • Systematically compare NUP188 levels and localization patterns across healthy and pathological tissues

  • Employ tissue microarrays with NUP188 antibodies for high-throughput screening across multiple disease states

  • Correlate alterations with clinical parameters to identify potential biomarker applications

• Post-translational modification assessment:

  • Develop modification-specific antibodies (phospho-NUP188, etc.) to track regulatory changes

  • Implement dual staining with pan-NUP188 and modification-specific antibodies to calculate modified/total ratios

  • Apply these tools to study how signaling pathways affect NPC function in disease contexts

• Protein-protein interaction disruption studies:

  • Use NUP188 antibodies in proximity ligation assays to visualize interactions with transport factors

  • Quantify changes in interaction networks in disease models

  • Employ antibodies in IP-MS experiments to detect altered NUP188 interaction partners in pathological states

• Therapeutic response monitoring:

  • Assess NUP188 localization and expression changes following experimental therapeutics

  • Develop high-content screening approaches using NUP188 antibodies to identify compounds that restore normal nuclear transport

• Single-cell analysis applications:

  • Adapt NUP188 antibody protocols for single-cell immunofluorescence analysis

  • Integrate with single-cell transcriptomics to correlate protein localization with gene expression patterns

  • Employ imaging mass cytometry with NUP188 antibodies for multiplexed analysis in tissue context

These approaches provide a framework for leveraging NUP188 antibodies to uncover the mechanistic connections between nuclear transport defects and disease pathogenesis, potentially revealing novel therapeutic targets .

What are the emerging applications of NUP188 antibodies in studying cellular senescence and aging processes?

The application of NUP188 antibodies in cellular senescence and aging research represents an expanding frontier with several methodological opportunities:

• Age-related NPC composition changes:

  • Implement quantitative immunofluorescence protocols with NUP188 antibodies across age series

  • Develop standardized image analysis workflows to detect subtle changes in NUP188 distribution

  • Compare NUP188 localization with other NPC components to identify differential turnover rates

• Senescence-associated NPC alterations:

  • Establish dual staining protocols combining NUP188 antibodies with senescence markers (p16, SA-β-gal)

  • Quantify changes in nuclear envelope morphology and NUP188 distribution in senescent cells

  • Correlate altered nuclear transport capacity with NUP188 distribution changes

• Rejuvenation intervention assessment:

  • Apply NUP188 antibody-based assays to evaluate the effectiveness of interventions targeting age-related nuclear transport defects

  • Develop high-throughput screening platforms to identify compounds restoring proper NUP188 localization

• Tissue-specific aging differences:

  • Compare NUP188 distribution in post-mitotic tissues (brain, heart) versus proliferative tissues

  • Correlate tissue-specific aging phenotypes with differential NUP188 alterations

  • Develop multiplex protocols to simultaneously visualize NUP188 and tissue-specific markers

• Single-cell heterogeneity in aging:

  • Implement NUP188 antibodies in single-cell analysis platforms to assess cell-to-cell variability

  • Correlate nuclear transport efficiency with NUP188 distribution at the single-cell level

  • Develop computational approaches to classify cells based on NUP188 patterns as biomarkers of cellular aging

These methodological approaches enable researchers to investigate the still-emerging connections between nuclear pore complex integrity, nucleocytoplasmic transport efficiency, and cellular aging processes, potentially revealing novel interventional targets for age-related diseases .